ViaCyte Raises $5.4M

San Diego-based ViaCyte, a biopharmaceuticals startup developing stem-cell based treatments for diabetes, said late Friday that it has raised $5.4M in a Series C-1 funding round. The company said the funding came from an un-named, nonprofit corporation and several individuals. The funding comes on top of an existing, Series C-1 financing which occurred in July of 2013, bringing that total round to $16.5M. ViaCyte said it will use the new funds for clinical development efforts. ViaCYte is led by Paul Laikind. More information »